JP2021536454A5 - - Google Patents

Info

Publication number
JP2021536454A5
JP2021536454A5 JP2021510859A JP2021510859A JP2021536454A5 JP 2021536454 A5 JP2021536454 A5 JP 2021536454A5 JP 2021510859 A JP2021510859 A JP 2021510859A JP 2021510859 A JP2021510859 A JP 2021510859A JP 2021536454 A5 JP2021536454 A5 JP 2021536454A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
patient
per
total selenium
Prior art date
Application number
JP2021510859A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020043762A5 (https=
JP7420791B2 (ja
JP2021536454A (ja
Filing date
Publication date
Priority claimed from EP18191289.0A external-priority patent/EP3616693A1/en
Application filed filed Critical
Publication of JP2021536454A publication Critical patent/JP2021536454A/ja
Publication of JPWO2020043762A5 publication Critical patent/JPWO2020043762A5/ja
Publication of JP2021536454A5 publication Critical patent/JP2021536454A5/ja
Application granted granted Critical
Publication of JP7420791B2 publication Critical patent/JP7420791B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021510859A 2018-08-28 2019-08-28 ハイリスクヒトパピローマウイルス感染症の治療 Active JP7420791B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18191289.0A EP3616693A1 (en) 2018-08-28 2018-08-28 Therapy of high-risk human papillomavirus infections
EP18191289.0 2018-08-28
PCT/EP2019/072926 WO2020043762A1 (en) 2018-08-28 2019-08-28 Therapy of high-risk human papillomavirus infections

Publications (4)

Publication Number Publication Date
JP2021536454A JP2021536454A (ja) 2021-12-27
JPWO2020043762A5 JPWO2020043762A5 (https=) 2022-08-10
JP2021536454A5 true JP2021536454A5 (https=) 2022-08-10
JP7420791B2 JP7420791B2 (ja) 2024-01-23

Family

ID=63442535

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510859A Active JP7420791B2 (ja) 2018-08-28 2019-08-28 ハイリスクヒトパピローマウイルス感染症の治療

Country Status (25)

Country Link
US (2) US20210299163A1 (https=)
EP (2) EP3616693A1 (https=)
JP (1) JP7420791B2 (https=)
CN (1) CN112584828A (https=)
AR (1) AR116027A1 (https=)
AU (1) AU2019332079B2 (https=)
BR (1) BR112021003360A2 (https=)
CA (1) CA3107691C (https=)
CL (1) CL2021000197A1 (https=)
EA (1) EA202190441A1 (https=)
ES (1) ES2958808T3 (https=)
GE (2) GEAP202215586A (https=)
HR (1) HRP20231470T1 (https=)
HU (1) HUE064691T2 (https=)
IL (1) IL281080B2 (https=)
MA (1) MA53482B1 (https=)
MD (1) MD3843715T2 (https=)
MX (1) MX2021002310A (https=)
PL (1) PL3843715T3 (https=)
RS (1) RS64916B1 (https=)
SM (1) SMT202300340T1 (https=)
TW (1) TWI827652B (https=)
UA (1) UA127632C2 (https=)
WO (1) WO2020043762A1 (https=)
ZA (1) ZA202100375B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3875083A1 (en) * 2020-03-03 2021-09-08 Selo Medical GmbH Composition for use in a treatment of cervical cell abnormalities comprising selenite compound and acid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2245301C2 (ru) 2000-05-10 2005-01-27 Окофарм Форшунгс-Унд Энтвиклюнгс-Гмбх Способ уменьшения площади поверхности диоксида кремния
AT412758B (de) 2000-06-05 2005-07-25 Vis Vitalis Lizenz & Handels Verwendung einer selenithältigen lösung zur behandlung viraler erkrankungen
AT412448B (de) 2001-02-13 2005-03-25 Vis Vitalis Lizenz & Handels Verwendung von selenhältigen präparaten
AT412703B (de) * 2001-12-04 2005-06-27 Vis Vitalis Lizenz & Handels Verwendung von selenithältigen präparaten zur topischen oder bukkalen anwendung
AT511159A1 (de) * 2011-02-16 2012-09-15 Selo Medical Gmbh Pharmazeutische zusammensetzungen enthaltend selenit- oder selenathältige verbindungen

Similar Documents

Publication Publication Date Title
JP2023002662A5 (https=)
Kimberlin Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis
JP6816098B2 (ja) 粘膜炎症を抑制するためのイガイ接着タンパク質生成物及びその使用
CN102670588B (zh) 鞣花酸用于制备抗病毒药物的应用
JP2006512413A5 (https=)
US6403618B1 (en) Agent and method for controlling angiogenesis
CN101181636B (zh) 一种防治人乳头瘤病毒感染的复方疫苗组合物、复方疫苗阴道喷雾剂及其用途
JP2021536454A5 (https=)
AU2012219005B2 (en) Pharmaceutical preparation containing selenite or selenite-containing compounds for treating cervical dysplasia or carcinomas
CN114053475A (zh) 一种抗hpv医用妇科敷料
CN103599093B (zh) 一种抗hpv药物制剂及用途
HRP20231470T1 (hr) Terapija za infekcije humanim papilomavirusom visokog rizika
IL296146A (en) Preparations containing compounds containing selenite for use in the treatment of cervical cell abnormalities
DeRossi et al. The management of oral human papillomavirus with topical cidofovir: a case report
JPWO2021175877A5 (https=)
JPWO2020043762A5 (https=)
JPH10175852A5 (https=)
US20130287812A1 (en) anti-HPV drug and its application in preparing medicines for treatment of HPV (human papilloma virus) infection
RU2249465C1 (ru) Способ лечения и профилактики иммунодефицитных состояний и заболеваний, связанных с бактериальной или вирусной агрессией
EP4046646A1 (en) Pharmaceutical composition for the treatment of hpv infections
CN115581760A (zh) 一种用于hpv病毒防治的凝胶及其制备方法
HK1243360B (zh) 用於治疗子宫颈非典型性增生或子宫颈癌的包含亚硒酸盐或含亚硒酸盐化合物的药物制剂